Equity to Asset ratio is calculated as total stockholders equity divided by total asset. InterMune's Total Stockholders Equity for the quarter that ended in Jun. 2014 was €250.27 Mil. InterMune's Total Assets for the quarter that ended in Jun. 2014 was €474.00 Mil.
Therefore, InterMune's Equity to Asset Ratio for the quarter that ended in Jun. 2014 was 0.53.
The historical rank and industry rank for InterMune's Equity-to-Asset or its related term are showing as below:
FRA:IUX'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.92 Med: 0.26 Max: 0.98
Current: 0.53
During the past 13 years, the highest Equity to Asset Ratio of InterMune was 0.98. The lowest was -0.92. And the median was 0.26.
FRA:IUX's Equity-to-Asset is not ranked
in the Biotechnology industry.
Industry Median: 0.66
vs FRA:IUX: 0.53
InterMune Equity-to-Asset Historical Data
The historical data trend for InterMune's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of InterMune's Equity-to-Asset
For the Biotechnology subindustry, InterMune's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InterMune's Equity-to-Asset Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, InterMune's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where InterMune's Equity-to-Asset falls into.
InterMune Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
InterMune's Equity to Asset Ratio for the fiscal year that ended in Dec. 2013 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InterMune (FRA:IUX) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
InterMune Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of InterMune's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
InterMune, Inc was incorporated in California in 1998 and reincorporated in Delaware in 2000 in connection with its initial public offering. InterMune is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases. The Company's business is mainly focused on the development and commercialization of therapies within the specialized areas of pulmonology and orphan fibrotic diseases. It has an advanced-stage product candidate in pulmonology, pirfenidone that was granted marketing authorization effective February 2011 in all 27 member countries of the European Union for the treatment of adults with mild to moderate idiopathic pulmonary fibrosis. Pirfenidone is an orally active, small molecule compound under development for the treatment of idiopathic pulmonary fibrosis. Pirfenidone, a treatment for IPF, a progressive and fatal lung disease, has completed the global Phase 3 CAPACITY clinical development program. Actimmune is currently approved in the United States for the treatment of chronic granulomatous disease and severe, malignant osteopetrosis. Actimmune is also approved for commercial use in both indications in numerous other countries. CGD is a life-threatening congenital disorder that causes patients, mainly children, to be vulnerable to severe, recurrent bacterial and fungal infections. This results in frequent and prolonged hospitalizations and commonly results in death. Severe, malignant osteopetrosis is a life-threatening, congenital disorder that mainly affects children. This disease results in increased susceptibility to infection and an overgrowth of bony structures that might lead to blindness and/or deafness. The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacture and marketing of pharmaceutical products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:IUX has been successfully added to your 